---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-23-000035"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:40:30.082283+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mineralys Q1 net loss $12.6M from $7.6M YoY; cash $301.8M; Lorundrostat pivotal trial dosed

## Summary
- Net loss $12.6M vs $7.6M in Q1 2022; R&D expense $12.3M (up from $6.8M) driven by $4.0M milestone payment to Mitsubishi Tanabe.
- Cash, equivalents & investments $301.8M as of Mar 31, 2023, up from $110.1M; expected to fund operations through mid-2025.
- Initiated Advance-HTN Phase 2 pivotal trial (lorundrostat) in April 2023; topline data expected H1 2024.
- Plans to initiate Launch-HTN Phase 3 (H2 2023) and a CKD Phase 2 trial (mid-2023); Launch-HTN data expected mid-2025.

## SEC filing metadata
- accession: 0001933414-23-000035
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/0001933414-23-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/mlys-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-23-000035
- JSON: https://secwatch.observer/filing/0001933414-23-000035.json
- Plain text: https://secwatch.observer/filing/0001933414-23-000035.txt

## Key facts
- Earnings Releases
  Mineralys Therapeutics, Inc. reported first quarter 2023 results: net income $12.6 million.
  - Period: first quarter 2023
  - Net income: $12.6 million
  - Result: reported results
  source text: Net loss was $12.6 million for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/0001933414-23-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.